{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:18:59Z","timestamp":1787894339272,"version":"build-2784847793"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Botulinum toxin type A (BoNT-A) is used as a targeted treatment for upper-limb essential tremor, but uncertainty remains regarding the magnitude and certainty of its benefits and harms. We evaluated the efficacy and safety of BoNT-A compared with placebo in adults with upper-limb essential tremor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched bibliographic databases, trial registries, and eligible grey-literature sources from inception to July 20, 2026. We included randomized placebo-controlled trials of BoNT-A in adults with upper-limb essential tremor. Primary outcomes were short-term clinician-rated upper-limb tremor severity and muscular weakness through Week 24. Continuous outcomes were summarized using mean differences or Hedges\u2019 g, and binary safety outcomes using risk differences. Random-effects meta-analyses were performed. Risk of bias was assessed at the result level using the Cochrane Risk of Bias 2 tool, and certainty of evidence was evaluated using GRADE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Three trials with outcome data from 231 participants contributed to the primary efficacy analysis. BoNT-A reduced short-term clinician-rated upper-limb tremor severity compared with placebo (Hedges\u2019 g, \u22120.66; 95% CI, \u22120.94 to \u22120.38; I\n                      <jats:sup>2<\/jats:sup>\n                      =\u202f0%; moderate-certainty evidence). Muscular weakness was more frequent with BoNT-A (2 trials; 107 participants; risk difference, 0.19; 95% CI, 0.06 to 0.32; I\n                      <jats:sup>2<\/jats:sup>\n                      =\u202f29%; low-certainty evidence), approximately 190 more participants per 1,000 treated. BoNT-A may improve investigator-rated global treatment response (Hedges\u2019 g, 0.70; 95% CI, 0.06 to 1.34) and patient-rated global treatment response (Hedges\u2019 g, 0.40; 95% CI, 0.14 to 0.67), although certainty was low. Maximum grip strength was reduced (mean difference, \u22127.13\u202fkg; 95% CI, \u221211.42 to \u22122.85; low-certainty evidence). Evidence regarding treatment-related adverse events was very uncertain, whereas estimates for serious adverse events and discontinuation due to adverse events were too imprecise to exclude clinically important benefit or harm.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>BoNT-A probably reduces short-term clinician-rated upper-limb tremor severity but may increase muscular weakness and reduce grip strength. Evidence for global treatment response and less frequent adverse outcomes remains limited or very uncertain. Treatment decisions should balance the expected reduction in tremor against the individualized risk of weakness and functional impairment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1886329","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:32:21Z","timestamp":1787891541000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of botulinum toxin type a for upper-limb essential tremor: a systematic review and meta-analysis of randomized placebo-controlled trials"],"prefix":"10.3389","volume":"17","author":[{"given":"Guorui","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Clinical Test Labs, Handan First Hospital","place":["Handan, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Second Neurology, Handan First Hospital","place":["Handan, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Second Neurology, Handan First Hospital","place":["Handan, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/mds.27121","article-title":"Consensus statement on the classification of tremors. From the task force on tremor of the International Parkinson and Movement Disorder Society","volume":"33","author":"Bhatia","year":"2018","journal-title":"Mov Disord"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ncl.2020.01.002","article-title":"Current and emerging treatments of essential tremor","volume":"38","author":"Ondo","year":"2020","journal-title":"Neurol Clin"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1056\/NEJMcp1707928","article-title":"Essential tremor","volume":"378","author":"Haubenberger","year":"2018","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1212\/WNL.36.7.1001","article-title":"Disability in essential tremor: effect of treatment","volume":"36","author":"Koller","year":"1986","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1212\/WNL.39.12.1587","article-title":"Acute and chronic effects of propranolol and primidone in essential tremor","volume":"39","author":"Koller","year":"1989","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1212\/WNL.0b013e318236f0fd","article-title":"Evidence-based guideline update: treatment of essential tremor","volume":"77","author":"Zesiewicz","year":"2011","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/mds.27700","article-title":"MDS evidence-based review of treatments for essential tremor","volume":"34","author":"Ferreira","year":"2019","journal-title":"Mov Disord"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/mds.70184","article-title":"Update on medical treatments for essential tremor: an International Parkinson and Movement Disorder Society evidence-based medicine review","volume":"41","author":"Dash","year":"2026","journal-title":"Mov Disord"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"120203","DOI":"10.1016\/j.jns.2022.120203","article-title":"Botulinum toxin for the treatment of tremor","volume":"435","author":"Mittal","year":"2022","journal-title":"J Neurol Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/toxins13010042","article-title":"Botulinum toxin in movement disorders: an update","volume":"13","author":"Anandan","year":"2021","journal-title":"Toxins"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"108273","DOI":"10.1016\/j.toxicon.2025.108273","article-title":"Botulinum toxin for essential tremor","volume":"256","author":"Gulati","year":"2025","journal-title":"Toxicon"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.5603\/PJNNS.a2020.0079","article-title":"Botulinum toxin type a for hand tremor: a meta-analysis of randomised controlled trials","volume":"54","author":"Zheng","year":"2020","journal-title":"Neurol Neurochir Pol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3390\/toxins14030203","article-title":"Botulinum toxin for essential tremor and hands tremor in neurological diseases: a meta-analysis of randomized controlled trials","volume":"14","author":"Liao","year":"2022","journal-title":"Toxins"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1056\/NEJMoa2304192","article-title":"Trial of botulinum toxin for isolated or essential head tremor","volume":"389","author":"Marques","year":"2023","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1212\/WNL.45.4.822","article-title":"Botulinum toxin treatment of essential head tremor","volume":"45","author":"Pahwa","year":"1995","journal-title":"Neurology"},{"key":"ref16","year":""},{"key":"ref17","year":""},{"key":"ref18","year":""},{"key":"ref19","author":"Patterson","year":"2024"},{"key":"ref20","year":"2025"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref22","author":"Higgins","year":"2024"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1002\/1097-0258(20001130)19:22<3127::AID-SIM784>3.0.CO;2-M","article-title":"A simple method for converting an odds ratio to effect size for use in meta-analysis","volume":"19","author":"Chinn","year":"2000","journal-title":"Stat Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jclinepi.2022.07.014","article-title":"GRADE guidance 34: update on rating imprecision using a minimally contextualized approach","volume":"150","author":"Zeng","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.parkreldis.2018.06.019","article-title":"Botulinum toxin in essential hand tremor\u2014a randomized double-blind placebo-controlled study with customized injection approach","volume":"56","author":"Mittal","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1212\/WNL.56.11.1523","article-title":"A randomized, double-masked, controlled trial of botulinum toxin type a in essential hand tremor","volume":"56","author":"Brin","year":"2001","journal-title":"Neurology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/mds.870110306","article-title":"A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type a in essential hand tremor","volume":"11","author":"Jankovic","year":"1996","journal-title":"Mov Disord"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3390\/toxins12120807","article-title":"Tolerability and efficacy of customized incobotulinumtoxinA injections for essential tremor: a randomized, double-blind, placebo-controlled study","volume":"12","author":"Jog","year":"2020","journal-title":"Toxins"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e0153739","DOI":"10.1371\/journal.pone.0153739","article-title":"Functional ability improved in essential tremor by incobotulinumtoxinA injections using kinematically determined biomechanical patterns","volume":"11","author":"Samotus","year":"2016","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"684835","DOI":"10.3389\/fneur.2021.684835","article-title":"Tremor syndromes: an updated review","volume":"12","author":"Lenka","year":"2021","journal-title":"Front Neurol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12874-015-0091-1","article-title":"Hartung\u2013Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies","volume":"15","author":"R\u00f6ver","year":"2015","journal-title":"BMC Med Res Methodol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1886329\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:32:30Z","timestamp":1787891550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1886329\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":34,"alternative-id":["10.3389\/fneur.2026.1886329"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1886329","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"1886329"}}